leadf
logo-loader
viewBT Group PLC

Market report: FTSE gains after US regulators approve use of plasma to treat Covid-19

The FTSE has taken its cue from global markets overnight after a coronavirus treatment was approved by US regulators.

BT (LON:BT.A) is gaining after reports it has called in Goldman Sachs following a protracted sell-off of the shares.

Bunzl (LON:BNZL) is in positive territory after it resumed dividend payments following a strong jump in profits after a boost in demand for COVID-19 related products and grocery items.

AstraZeneca (LON:AZN) is up after US President Donald Trump suggested he was willing to fast-track a vaccine being developed by the company with Oxford University.

Meanwhile - Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has received a US patent for its TZLS-501 antibody technology being developed to treat the life-threatening effects of the coronavirus (COVID-19).

Elsewhere - Base Resources (LON:BSE) delivered profits of US$39.6mln, and has declared their maiden dividend after the company said its operations in Kenya maintained production during the coronavirus crisis. 

Blackbird Plc (LON:BIRD) has revealed that its cloud video editing platform has been selected by production company Live X for use at the US Democratic National Convention, which was held from Monday to Thursday last week.

Shanta Gold Ltd (LON:SHG) posts revenue of US$73mln from gold production at its mine in Tanzania during the six months to 30 June 2020, up from US$53.6mln last year.

Quick facts: BT Group PLC

Price: 101.15 GBX

LSE:BT.A
Market: LSE
Market Cap: £10.03 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company. Peyton says the merger will accelerate and de-risk 4D's admission to...

3 hours, 58 minutes ago

2 min read